Uremic pericarditis

Article written and reviewed by Dr Luca Moretti

The uremic pericarditis is inflammation of the pericardium associated with advanced renal failure and the uremic metabolic milieu, after evaluation of other possible causes. It may occur in untreated chronic kidney disease or during severe acute kidney injury. The traditional definition includes episodes occurring before dialysis or within the first eight weeks after its initiation; beyond that interval the condition is generally termed dialysis-associated pericarditis.

This distinction is temporal and does not prove the existence of two completely separate mechanisms. In patients already receiving dialysis, missed sessions, inadequate treatment, or an increased catabolic load may recreate a uremic setting. It is equally important to distinguish pericarditis from a simple effusion caused by volume overload, venous hypertension, or hypoalbuminemia: the mere presence of fluid in a patient with kidney disease does not by itself justify attribution to uremic inflammation.

Management centers on correcting inadequate clearance and assessing hemodynamics. Dialysis is the fundamental treatment for truly uremic forms, but it must not delay decompression of cardiac tamponade. Drugs commonly used in nonuremic pericarditis have efficacy and safety limitations in this setting that prevent automatic application of standard regimens.

Etiology, classification, and predisposing factors

The advanced renal failure creates an environment characterized by retained solutes, metabolic abnormalities, and inflammatory activation. Pericarditis is a clinical manifestation of this setting, not the proven consequence of a single measurable substance. Urea and creatinine describe aspects of renal dysfunction, but there is no universally diagnostic threshold value for pericarditis. Marked azotemia may increase plausibility, whereas a relatively lower value after a session does not rule out disease that is already established.

The dialysis-associated pericarditis is conventionally defined as occurring after at least eight weeks of kidney replacement therapy. The threshold helps describe case series and disease course but should not be interpreted as proof that clearance is adequate. Evaluation includes sessions actually delivered, their duration, vascular access, recirculation, and delivered dialysis dose. A patient formally enrolled in a dialysis program may still receive inadequate treatment because of technical problems, interruptions, or changing metabolic requirements.

The catabolic conditions, such as major infections or other acute illnesses, may increase the solute load and render a previously adequate prescription insufficient. Malnutrition and hypoalbuminemia are often associated with greater clinical complexity and may promote effusion through additional mechanisms. The significance of these factors must be distinguished: some contribute to pericarditis, others to fluid accumulation or prognosis. Seeking a single explanation may overlook treatable components that coexist in the same patient.

The volume overload may cause an effusion without inflammation, especially in the presence of heart failure or impaired lymphatic resorption. This situation may overlap with pericarditis and modify its signs. Weight reduction during dialysis does not by itself demonstrate resolution of the inflammatory component, just as a persistent effusion does not automatically mean inadequate clearance. Interpretation requires the clinical course, echocardiography, and review of the different mechanisms of fluid production and resorption.

The alternative causes remain numerous: infections, tuberculosis, malignancy, autoimmune diseases, myocardial infarction, and drugs may also affect patients with renal failure. An infected vascular access can cause bacteremia, whereas immunosuppressive therapy increases the risk of opportunistic pathogens. The diagnosis of uremic pericarditis is therefore clinical and contextual, supported by the absence of a more convincing explanation and by response to correction of uremia, although the latter is not absolute etiologic proof.

The epidemiology has changed with earlier access to kidney replacement therapy and evolving dialysis techniques. Percentages from historical series depend on era, diagnostic criteria, and selected populations and do not automatically describe the current risk of every patient. The complication remains clinically important precisely because it may be minimally symptomatic until a significant effusion develops. Recognition requires attention to changes in the clinical picture, not screening based solely on a laboratory value.

Pathogenesis and cardiorenal pathophysiology

The pericardial injury may have a fibrinous or serofibrinous appearance, with inflammatory infiltration and deposition of material on the surfaces of the pericardial layers. Uremia alters several cellular and vascular systems, but the specific contribution of individual solutes to the disease has not been definitively clarified. Response to dialysis supports the importance of the metabolic milieu without proving that urea itself is the direct mediator. It is therefore inappropriate to describe the disease as simple precipitation of nitrogenous substances on the cardiac surface.

The exudation and reduced resorption may coexist with elevated venous pressures and reduced oncotic pressure. The resulting effusion often reflects a combination of inflammation and altered fluid balance. This composition explains why solute clearance and volume removal are not perfectly equivalent interventions. A session with aggressive ultrafiltration may reduce weight without sufficiently correcting the uremic milieu and, in the presence of cardiac compression, may worsen perfusion.

The platelet dysfunction associated with uremia and exposure to anticoagulants may favor a hemorrhagic component of the fluid. Blood in the effusion does not, however, identify the cause: malignancy, procedural trauma, and other conditions must be considered. Bleeding may accelerate accumulation and increase the risk of tamponade. Hemostatic assessment should include drugs, platelet count, and the clinical context, remembering that normal conventional coagulation tests do not fully characterize uremic platelet dysfunction.

The tamponade develops when pericardial pressure impedes filling. A hypervolemic patient may initially maintain intracardiac pressures high enough to mask part of the obstruction; rapid volume removal can reduce this compensation. Hypotension during dialysis should therefore not always be attributed to excessive ultrafiltration without evaluating the pericardium. The presence of a large collection requires consideration of the transmural pressure gradient and preload, in addition to total body water.

The ventricular interdependence becomes relevant when a rigid or pressurized sac limits chamber expansion. Respiration changes venous return and may accentuate competition for the available volume. With fibrotic evolution, constrictive physiology may develop, sometimes becoming evident after drainage. Persistent congestion should not automatically be attributed to the pericardium: uremic cardiomyopathy, valvular disease, and ventricular dysfunction may produce similar findings and require integrated interpretation of imaging and hemodynamics.

The cardiorenal circulation may worsen when reduced cardiac output and elevated venous pressure further compromise residual renal function. Oliguria, hypotension, and worsening perfusion indices may result from compression in addition to the underlying kidney disease. Decompression may improve this component but does not correct advanced structural renal disease. Distinguishing reversible from irreversible components helps determine the timing of interventions without waiting for dialysis alone to resolve every aspect of the picture.

Clinical manifestations and bedside assessment

The chest pain may be pleuritic and positional, but in uremic forms it may be mild or absent. Dyspnea, malaise, and reduced tolerance of dialysis may dominate the presentation. A pericardial friction rub is an important finding when present and should be sought carefully, without considering its absence exclusionary. The disease may be discovered during investigation of an effusion or of hemodynamic deterioration not explained by the usual volume balance.

The dialysis history must be concrete: missed or shortened sessions, achieved flows, alarms, access problems, changes in urine output, and recent hospitalizations. An adequate prescription on paper may not correspond to the treatment actually delivered. Infections, procedures, trauma, medications, and anticoagulation should also be reconstructed. In a patient not yet receiving dialysis, the trajectory of renal function, uremic symptoms, and concurrent complications are assessed; the indication for kidney replacement therapy arises from the clinical picture, not from an isolated filtration threshold.

The clinical tamponade may present with tachycardia, narrowed pulse pressure, hypotension, jugular venous distention, and pulsus paradoxus, but presentation is variable. Pre-existing hypertension and volume overload may make a relatively low pressure for that individual less obvious. Deterioration during or after ultrafiltration requires urgent reassessment. The classic triad should not be awaited before echocardiography, particularly with increasing dyspnea, oliguria, or altered mental status.

The volume signs include edema, weight changes, pulmonary congestion, and venous pressure. They should be interpreted together: peripheral edema and reduced effective arterial blood volume may coexist. Estimated dry weight does not directly measure chamber filling when the pericardium is pressurized. Improvement in dyspnea after a session may reflect reduced pulmonary congestion while a clinically relevant pericardial collection remains present and requires specific follow-up.

The fever requires evaluation for possible infection, particularly of vascular access, the endocardium, and thoracic sites. An effusion associated with bacteremia cannot be classified as uremic solely because renal failure is present. Weight loss, sweats, or a subacute course may suggest tuberculosis or malignancy, although they remain nonspecific. Correct diagnosis requires assigning symptoms to the most plausible mechanism after appropriate testing rather than attributing every abnormality to known kidney disease.

The severity assessment includes perfusion, respiratory status, electrolytes, and cardiac rhythm. Hyperkalemia, acidosis, and pulmonary edema may require urgent treatment alongside pericarditis and complicate the sequence of interventions. The decision between initial decompression and immediate dialysis should be shared in a setting capable of managing both needs. If significant compression is present, an overly aggressive dialysis procedure may be dangerous; if it is absent, delaying correction of severe uremia may prolong injury.

Investigations, diagnosis, and distinction from other causes

The echocardiogram is central for measuring the distribution and size of the effusion, assessing chamber collapse, and studying respiratory flow variation. It should include ventricular function and concomitant disease. Signs of tamponade should not be interpreted separately from blood pressure and volume status; some conditions modify their sensitivity. Serial comparison is particularly useful during treatment because it documents whether fluid decreases, remains stable, or increases as the patient’s fluid balance changes.

The electrocardiogram may not show the typical diffuse ST-segment elevations or PR depression. Their absence does not exclude uremic pericarditis. Low voltages and electrical alternans may accompany large collections, whereas hyperkalemia and pre-existing heart disease complicate interpretation. Troponin may be chronically elevated in kidney disease: an isolated value does not distinguish ischemia, myocarditis, and chronic injury. Trends, symptoms, and imaging are needed when a myocardial or coronary complication is suspected.

The laboratory tests include complete blood count, inflammatory markers, urea, creatinine, electrolytes, albumin, and liver function, with cultures or etiologic tests according to suspicion. No blood test alone confirms uremic pericarditis. Dialysis dose is assessed with indicators appropriate to the treatment modality, integrated with symptoms and access performance. A satisfactory clearance index on one measurement does not exclude previous periods of underdialysis or clinical problems not represented by that parameter.

The CT is useful for loculated collections, calcifications, thickening, and alternative thoracic diagnoses. Cardiac magnetic resonance may characterize the pericardium and myocardium when the result changes management; if contrast is considered, product selection and renal-risk assessment are required. It is incorrect to indiscriminately transfer the limitations of every older contrast agent to current practice. In an unstable situation, no anatomic investigation should delay echocardiography and treatment of hemodynamic compromise.

If pericardial drainage is performed, the fluid should be examined for cells, microbiology, and cytology, with targeted testing for mycobacteria or other causes when indicated. A serosanguineous exudate may be compatible with uremia but is not specific. There is no fluid marker that certifies a uremic origin. Biopsy may be useful in selected situations, especially if a surgical procedure is necessary or if suspicion persists for a cause not clarified by less invasive testing.

The final diagnosis integrates advanced kidney disease, evidence of pericardial inflammation, the dialysis context, and absence of a more convincing alternative cause. Improvement after intensified dialysis is consistent with the hypothesis but may also include reduction in volume overload. An incomplete response should prompt reassessment of anatomy, adherence, and diagnosis rather than automatic declaration of refractory pericarditis. The distinction from neoplastic involvement or infection remains important even after initial clinical improvement.

Dialysis, volume management, and anticoagulation

The kidney replacement therapy should be initiated promptly when pericarditis is attributed to uremia in a patient not yet receiving dialysis. In patients already treated, causes of inadequate clearance are corrected and an intensified program is considered. The choice of modality and frequency depends on stability, access, and concurrent needs. The goal is to improve the metabolic milieu safely, not to obtain a rapid change in a single laboratory value at the cost of circulatory instability.

The intensified dialysis may involve more frequent sessions during an initial period, with close clinical and echocardiographic reassessment. Frequency, duration, and follow-up interval are individualized according to response. Forms occurring before dialysis initiation have historically tended to respond better than episodes arising during already adequate treatment, but this observation does not predict the individual case with certainty. A patient with an enlarging effusion should not continue the same program indefinitely merely because the initial diagnosis was uremic.

The cautious ultrafiltration is essential when filling is preload-dependent. More frequent sessions may allow less volume removal per session. Intensification of clearance should not be confused with aggressive fluid removal. Hypotension, tachycardia, or symptoms during treatment require immediate review of the prescription and the pericardial situation. In cases with tamponade or physiology close to hemodynamic compromise, drainage may need to precede dialysis that would otherwise dangerously reduce venous return.

Management of circuit anticoagulation considers the risk of hemorrhagic effusion and bleeding. When appropriate, heparin-free strategies or regional anticoagulation may be used according to available modalities and expertise. These choices must be distinguished from any indication for systemic anticoagulation for a prosthetic valve, atrial fibrillation, or thromboembolism. Systemic therapy is not automatically stopped: the hemorrhagic and thrombotic risks must be weighed, particularly when indications are strong and not easily substituted.

Control of vascular access is part of causal therapy. Stenosis, inadequate flow, recirculation, or functional problems may prevent delivery of the prescribed dose. Infection and the need for interventions on the access must also be assessed. Technical correction is essential when it explains underdialysis, but it does not replace surveillance of the already present effusion. A newly effective access may improve clearance while the collection still requires time or direct intervention to resolve.

The therapeutic response includes reduction in symptoms and friction rub, improvement in inflammatory findings when interpretable, and regression of fluid. Outcomes should not be assessed only at the end of a predetermined course. Development of compression, enlargement of the collection, or lack of a favorable course requires reconsideration of drainage. Concurrent nutritional, metabolic, and infectious factors are corrected in parallel because an adverse clinical milieu can maintain the effusion even after clearance improves.

Drainage, drugs, and treatment of persistent cases

The urgent drainage is necessary when the effusion causes clinical tamponade. Dialysis does not provide immediate decompression and should not be used as a therapeutic trial in an unstable patient. Image-guided pericardiocentesis with catheter drainage permits evacuation and analysis of the material; a surgical approach may be preferable for unfavorable anatomy, loculations, organized material, or a need for biopsy. The decision depends on the specific condition and available expertise, not merely on the label of uremia.

A persistent large effusion requires individualized assessment even without shock. If the context suggests underdialysis and the patient is stable, a trial of intensified clearance under close surveillance may be reasonable. If clearance is already adequate, the fluid increases, or there is no clinical-anatomic response, the threshold for intervention becomes lower. Waiting periods of one or two weeks described in some strategies should not be treated as mandatory when signs of deterioration appear.

The pericardial window may provide drainage and diagnostic tissue, especially in recurrences or when a catheter does not control the collection. It does not, however, eliminate the uremic cause: without adequate kidney replacement therapy, fluid may recur. Similarly, cessation of output may reflect either emptying or drain obstruction and requires correlation with echocardiography. Assessment after decompression also evaluates possible persistence of effusive-constrictive physiology, which is not the same as simple residual fluid.

The NSAIDs are not the foundation of treatment for uremic pericarditis. Evidence of benefit on the collection and disease course is limited, while gastrointestinal toxicity, bleeding, and loss of residual renal function may be relevant. Colchicine carries a risk of accumulation and toxicity in severe renal failure, is not effectively removed by dialysis, and has potentially dangerous interactions. The standard regimen for idiopathic pericarditis should not be transferred to these patients; any exceptional use requires explicit specialist justification.

The corticosteroids may reduce inflammation in selected cases but increase the risk of infections and other complications and do not correct inadequate clearance. Their use requires reasoned exclusion of infectious causes and reassessment of the diagnosis. Interleukin-1 blockade likewise does not have the same evidence base as in idiopathic recurrent pericarditis for pure uremic disease. An inadequate response to dialysis does not automatically justify converting the pathway to immunomodulatory therapy without clarifying the persistent mechanism.

The pericardiectomy is considered for symptomatic irreversible chronic constriction after definition of physiology and assessment of risk. Advanced kidney disease, malnutrition, calcification, and cardiovascular comorbidities may increase operative complexity. Favorable outcomes in selected series should not be presented as guaranteed percentages for a patient on dialysis. The treatment plan must integrate the expected hemodynamic benefit, myocardial function, and the feasibility of managing kidney replacement therapy during the perioperative period and recovery.

Prognosis, complications, and prevention of recurrence

The prognosis improves when uremia is corrected and the effusion is recognized before hemodynamic compromise. Outcome nonetheless depends on the cause of kidney disease, cardiac function, and comorbidities. Historical series are not directly comparable with current dialysis programs, and specific data remain limited. Response should be described through control of inflammation, regression of the collection, and tolerance of kidney replacement therapy, distinguishing it from the overall course of kidney disease, which may remain severe even after pericardial resolution.

The tamponade is the main acute hemodynamic complication and may emerge during rapid volume changes. After effective drainage, new hypotension requires investigation for recurrence, bleeding, other causes of shock, or procedural complications. A hemorrhagic component requires review of hemostasis and medications. Blood-pressure control alone is insufficient: residual urine output, peripheral perfusion, mental status, and tolerance of dialysis sessions provide complementary information on circulatory recovery.

The recurrent effusion may result from persistent underdialysis, volume overload, incomplete diagnosis, or drainage problems. Reassessment must begin again from the clinical data and actual quality of therapy, without assuming that every new episode exactly reproduces the previous one. A neoplastic or infectious cause may only be recognized later. Fluid and tissue analysis, when available, must be integrated with the course rather than dismissed as irrelevant after an initial improvement.

The constriction should be suspected when congestion, ascites, or exercise limitation persist despite adequate volume control. Doppler and anatomic imaging help distinguish pericardial constraint, cardiomyopathy, and valvular disease. Calcification supports chronic damage but does not by itself measure functional impairment. Accurate diagnosis avoids both unnecessary surgery and prolonged attempts at dialysis that cannot correct an established fibrous peel.

The follow-up should initially be close and then adapted to clinical and echocardiographic regression. In patients treated conservatively, serial assessment is used to identify an unfavorable course early. After discharge, adherence, access, delivered dose, and weight are reassessed together with symptoms. There is no single schedule suitable for every residual effusion: size, rate of change, and reliability of outpatient monitoring should guide the frequency of testing.

The prevention is based on continuity of renal treatment, correction of problems causing incomplete sessions, and early recognition of catabolic conditions. It does not consist of indiscriminate prescription of anti-inflammatory drugs to patients on dialysis. The patient should know that new dyspnea, chest pain, syncope, or poor tolerance of sessions requires assessment. A shared nephrology-cardiology pathway allows rapid distinction among volume, inflammation, and compression problems, preventing interventions appropriate for one mechanism from worsening the others.

References
1. Schulz-Menger J et al. 2025 ESC Guidelines for the management of myocarditis and pericarditis. European Heart Journal. 2025;46(40):3952-4041.
2. Klein AL et al. Pericardial Diseases: International Position Statement on New Concepts and Advances in Multimodality Cardiac Imaging. JACC: Cardiovascular Imaging. 2024;17(8):937-988.
3. Adler Y et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC). Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2015;36(42):2921-2964.
4. Rosen RJ, Valeri AM. Management of Patients with Kidney Failure and Pericarditis. Clinical Journal of the American Society of Nephrology. 2023;18(2):270-272.
5. Rehman KA et al. Uremic pericarditis, pericardial effusion, and constrictive pericarditis in end-stage renal disease: Insights and pathophysiology. Clinical Cardiology. 2017;40(10):839-846.
6. Rutsky EA, Rostand SG. Treatment of uremic pericarditis and pericardial effusion. American Journal of Kidney Diseases. 1987;10(1):2-8.
7. Roberts WC. Pericardial heart disease: its morphologic features and its causes. Proceedings (Baylor University Medical Center). 2005;18(1):38-55.
8. Spodick DH. Acute cardiac tamponade. New England Journal of Medicine. 2003;349(7):684-690.
9. Welch TD et al. Echocardiographic diagnosis of constrictive pericarditis: Mayo Clinic criteria. Circulation: Cardiovascular Imaging. 2014;7(3):526-534.
10. Sagristà-Sauleda J et al. Effusive-constrictive pericarditis. New England Journal of Medicine. 2004;350(5):469-475.
11. U.S. National Library of Medicine. COLCHICINE tablet, film coated: prescribing information. DailyMed. n.d. Accessed September 26, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=50b9c910-49a3-4a57-80f5-dc36c09da4df.
12. Weinreb JC et al. Use of Intravenous Gadolinium-based Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation. Radiology. 2021;298(1):28-35.
13. Saab J et al. Diagnostic yield of cytopathology in evaluating pericardial effusions: Clinicopathologic analysis of 419 specimens. Cancer Cytopathology. 2017;125(2):128-137.